A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone

Summary

This study will test whether treatment with erlotinib plus SU011248 is better than erlotinib alone in patients with advanced/metastatic lung cancer who have received previous treatment with a platinum-based regimen.

Timeline

Start

2007-07

Primary completion

2010-07

Completion

2012-12

Outcome

Missed primary endpoint

registry analysis (superiority or other test); Sunitinib + Erlotinib vs Erlotinib; p = 0.1933; Hazard Ratio (HR) 0.942 (95% CI 0.822 to 1.079); Log Rank NCT00457392 ↗

Drugs

Indications